Cambridge-based PlaqueTec has appointed Dr Annalisa Jenkins – a biopharmaceutical and life sciences leader, veteran of the British Royal Navy and trained in cardiovascular medicine by the NHS – as its CEO. PlaqueTec was formed in 2008 within Papworth Hospital in Cambridge (UK), as a spinout from PA Consulting.
Annalisa will lead the 2018 launch of the biomarker-based PlaqueTec Liquid Biopsy System, designed to improve risk assessment and facilitate earlier intervention in the management of coronary artery disease – the leading cause of death worldwide. She has just completed her term as CEO of US-based Dimension Therapeutics and oversaw its recent sale to Ultragenyx. Previously, Annalisa held leadership positions at Merck Serono, and Bristol-Myers Squibb (BMS).
